Idera Pharmaceuticals Reports Positive Data From Ongoing Phase 1/2 Clinical Trial of IMO-8400 at #ASH2015

Idera Pharmaceuticals, Inc.

presented on Saturday, initial clinical data from its ongoing Phase 1/2 clinical trial for IMO-8400, a Toll-like receptor 7, 8 and 9 antagonist, being evaluated for the treatment of patients with relapsed or refractory Waldenström's Macroglobulinemia (WM).  These results provide evidence that IMO-8400 has clinical activity and is well tolerated.  Today's results were presented during a poster session (Abstract #1540) at the 57th Annual Meeting of the American Society of Hematology (ASH) in Orlando, FL. "Our clinical trial in Waldenström's Macroglobulinemia represents the first step in our understanding of the potential role that TLR antagonism could play in B-cell malignancies, specifically in those harboring the MYD88-L265P oncogenic mutation which is highly prevalent in Waldenström's Macroglobulinemia," stated Vincent Milano, Idera's Chief Executive Officer.  "We are pleased that the initial results from this ongoing trial met our objectives in determining safety and tolerability, as well as clinical activity of IMO-8400 in this patient population.  We are further encouraged that the safety profile seen to date will enable us to